Treatment resistant schizophrenia in Slovenian population
Abstract
Abstract
Background. Approximately 30 % of patients with schizophrenia do not achieve remission upon antipsychotic treatment. The purpose of this article is to present the differences between treatment resistant and treatment responsive patients in Slovenian population.
Methods. The prospective study included 138 patients diagnosed with schizophrenia according to DSM IV. They were divided in the treatment responsive (94 patients) and resistant group (44 patients). Groups were compared regarding the basic demographic and treatment related data.
Results. Our results showed gender-related differences; the treatment resistant group included more men than women (p = 0.021), and men were younger than women (p = 0.019). In the treatment resistant group the first psychotic episode occurred at a younger age (p = 0.005), on average it occured 3.86 years earlier than in the treatment responsive group. Treatment resistant patients had more hospitalizations (p = 0.001) and received higher doses of antipsychotic therapy in the past (p = 0.030) and present (p = 0.001). They were also prescribed clozapine earlier than the responsive group (p = 0.001). Regardless of the treatment response, patients living in a relationship had lower levels of total PANSS positive symptoms (p = 0.013) and total general symptoms (p = 0.050) than single and widowed patients.
Conclusions. We made a comparative study of a group of treatment resistant and treatment responsive schizophrenia patients in slovenian population for the first time. An early onset of the disease, male gender, more pronounced psychopathological symptoms and low global functioning can indicate increased risk for unfavourable disease progress. It is important that these patients are recognised early to ensure optimal treatment.
Downloads
References
Lindenmayer J-P, Bernstein-Hyman R, Grochowski S. Five-Factor Model of Schizophrenia Initial Validation. J Nerv Ment Dis 1994; 182: 631-8.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand 2009; 119: 7-14.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–75.
Overall JE, Gorham DR. Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962; 10: 799-812.
Richard CW, Hall MD. Global Assessment of Functioning: A Modified Scale. Psychosomatics 1995; 36: 267-75.
Mura G, Petretto DR, Bhat KM, Carta MG. Schizophrenia: from epidemiology to rehabilitation. Clin Pract Epidemiol Ment Health 2012; 8: 52-66.
Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980; 6: 592-605.
Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898-911.
Buckley PF, Shendarkar N. Treatment-refractory schizophrenia. Curr Opin Psychiatry 2005; 18: 165-73.
Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-9.
Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500-8.
Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11: 313-27.
Sensky T, Turkington D, Kingdon D, Scott, JL, Scott JS, Ronald S, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psych 2000; 57: 165-72.
Lindenmayer JP, Khan A. Assessment of therapy-resistant schizophrenia. Adv Biol Psychiatry 2010; 26: 9-32.
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-9.
Os Jv, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113: 91-5.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psych 1997; 154: 475-82.
McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13.
Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Shmushkevich M, Lubin G, et al. Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs. Schizophr Res 2007; 94: 45-9.
Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia. Evidence from meta-analysis. Arch Gen Psychiatry 2003; 60: 565-71.
James A, Crow YJ, Renowden S, Wardell AMJ, Smith DM, Anslow P. Is the course of brain development in schizophrenia delayed? Evidence from onsets in adolescence. Schizophr Res 1999; 40: 1-10.
Crow TJ. The »big bang« theory of the origin of psychosis and the faculty of language. Schizophr Res 2008; 102: 31-52.
Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001; 58: 1039-46.
Marcelis M, Navarro Mateu F, Murray R, Selten JP, Van Os J. Urbanization and psychosis: a study of 1942-1978 birth cohorts in the Netherlands. Psychol Med 1998; 28: 871-9.
Haukka J, Suvisaari J, Varilo T, Lonnqvist J. Regional variation in the incidence of schizophrenia in Finland: a study of birth cohorts born from 1950 to 1969. Psychol Med 2001; 31: 45-53.
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472-85.
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-804.
Castro APWd, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 2007; 29: 207-12.
Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6:134-44.
Xenitidis K, Campbell C, Mortimer A. Identifying treatment-resistant schizophrenia. Br J Psychiatry 2013; 202: 238.
de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. V tisku 2013.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
